Hepatitis B virus (HBV) is disease related to the liver.
Hepatitis B virus (HBV) infection results in deaths due to liver cancer and
liver failure. The hepatitis B vaccine is available for all age groups to
prevent HBV infection. The disease is caused due to transmission of Hepatitis B
virus (HBV) through contact with body fluids, blood and semen of an infected
person. Hepatitis B disease can cause acute and later may turn to chronic
disease if not treated at early stage. In 2015, WHO estimated that 240 Mn
people are infected with chronic hepatitis B virus. Every year more than
780,000 deaths occur due to complexity of hepatitis B viral infection. This
infection caused by chronic hepatitis B virus develops fulminant hepatitis B
(autoimmune disorder), liver cirrhosis, hepatocellular carcinoma (liver
cancer), liver failure which can be treated by a liver transplant. The Global
Alliance for Vaccines and Immunization (GAVI) provides direction and support to
prevent transmission through vaccination. However, there is a significant
decrease in incidence of hepatitis B virus infection after introduction of hepatitis
B vaccine.
The prophylactic hepatitis B virus vaccines market is
expected to grow remarkably during the forecast period due to increasing
prevalence and incidence of hepatitis B infection, increasing public awareness
(Patient Education Programs), government initiatives for promotion and creating
awareness about prophylactic hepatitis B vaccines. However, factors such as
side effects of the vaccine, high costs incurred during research and
development and macro-economic factors like stringent regulations can affect
the market adversely.
For detailed insights on enhancing your product
footprint, request for a Sample here @ https://www.persistencemarketresearch.com/samples/10571
The global prophylactic hepatitis b virus vaccines market is
classified on the basis of end use and geography.
Based on end use, the global prophylactic hepatitis B virus
vaccines market is divided into following:
- Hospitals
- Clinics
Ever since 1982, vaccines were available for prevention of
hepatitis B viral infections and currently more than 1 Bn doses of HBV vaccines
have been distributed worldwide. The WHO recommends that all infants should
receive the hepatitis B vaccine within 24 hours of birth. Thus, increase in the
population base in APAC is expected to contribute significantly to the growth
of global prophylactic hepatitis B virus vaccines market.
Geographically, the global prophylactic hepatitis b virus
vaccines market is segmented into five key regions: North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North America
dominates the global prophylactic hepatitis B virus vaccines market followed by
APAC and Europe. According to WHO, globally more than 240 Mn people suffer from
chronic hepatitis B viral infection and about 780,000 people die every year due
to consequences related with HBV infection. Of these majority of people belong
to developing nations of APAC, Latin America and Africa. The prevalence is
considerably low in countries with high level of living standards such as the
U.S., Canada, U.K., France, Germany, Italy and Spain.
To receive extensive list of important regions, ask for
TOC here @ https://www.persistencemarketresearch.com/toc/10571
Some of the major players operating in the market for
prophylactic hepatitis B virus vaccines are Merck & Co, Inc.,
Sanofi Pasteur, Novartis AG, Pfizer Inc., GlaxoSmithKline to name a few. Vaccine
market is an oligopolistic market in which the major players such as GlaxoSmithKline,
Merck & Co, Inc. and Sanofi Pasteur are using cost leadership and
differentiating strategy. The strategy of the major companies in the global
prophylactic hepatitis B virus vaccines market is to cut down the prices owing
to the increased demand.
Explore Extensive Coverage of Persistence Market
Research`s Healthcare Landscape
About
us:
Persistence
Market Research, as a 3rd-party research organization, does operate through an
exclusive amalgamation of market research and data analytics for helping
businesses ride high, irrespective of the turbulence faced on the account of
financial/natural crunches.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com